ARMK
Aramark
$56.49
+0.32 (+0.57%)
At close · Jul 8
Market Cap
$15.22B
Shares
262,953,564
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$56.49
Open$55.93
Day$55.87–56.89
52W$34.77–57.13
Avg vol 30d2.6M
Short int10.3M · 3.9% float · 4.2d
Short vol24%
Last earningsMay 12, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Moderate
Market backdrop
VIX 15.8 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+33%
above
Price vs 50-day avg
+9%
above
RSI (14)
68
neutral
MACD trend
Negative
52-week position
97%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+48%
trailing
YTD return
+54%
this year
Relative strength
+41%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $52 › 200d $43 — 50d above 200d
Institutional flow
Distributing
16 of 468 funds reported for Jun 30 · net -13.8K sh shares · +2 new
Insider flow
Distributing
Net -$974.2K over 90 days · 100% sells
Short interest
Falling
3.92% of float · ▼ -4.7% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
468 holders — near 3-yr high, broad support
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+6%
Y/Y
EPS growth
+23%
Y/Y
Valuation
P/E 43.2
in line
Buyback
$500.0M
authorized
Balance sheet
$639.1M
net cash
Quant / Vol
risk profile
Volatility
26%
annualized · 1-yr
Max drawdown
−18%
past year
ATR
2.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 11, 2026
Est · unconfirmed
· in 5 wks
FQ4-26 quarter ends
~Oct 2, 2026
Est
filed May 12, 2026
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+33%
Bullish
Price vs 50-day avg
+9%
Bullish
RSI (14)
68
Neutral
MACD trend
Negative
Bearish
52-week position
97%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $52 › 200d $43 — 50d above 200d
Institutional flow
Distributing
16 of 468 funds reported for Jun 30 · net -13.8K sh shares · +2 new
Insider flow
Distributing
Net -$974.2K over 90 days · 100% sells
Short interest
Falling
3.92% of float · ▼ -4.7% MoM · 4.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
468 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $35
Now $56 · 97%
52-wk high $57
vs 200-day avg +33%
vs 50-day avg +9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $0.49 | Q2 FY2026 | — |
| Adjusted Operating Income (AOI) non-GAAP | $258M | Q2 FY2026 | — |
|
|
|||
| New business wins | $1B | fiscal year to date | — |
| adjusted operating income (AOI) growth on constant currency basis non-GAAP | 24% | Q2 FY2026 call | — |
| AOI margin expansion non-GAAP | 50 | Q2 FY2026 call | — |
| calendar shift benefit to AOI non-GAAP | $25M | Q2 FY2026 call | — |
| client retention rate | 98% | Q2 FY2026 call | — |
| FSS U.S. organic revenue growth | 12% | Q2 FY2026 call | — |
| new client wins (fiscal year-to-date) | $1B | fiscal year-to-date call | — |
| organic revenue growth | 12% | Q2 FY2026 call | — |
| organic revenue growth (first half) | 8.5% | first half of fiscal 2026 call | — |
| Refreshments average size of new wins increase | 15% | Q2 FY2026 call | — |
| Alabama Department of Corrections facilities | 27 | Q1 FY2026 call | — |
| organic revenue | 5% | Q1 FY2026 call | — |
| organic revenue (FSS US) | 2% | Q1 FY2026 call | — |
| Penn Medicine beds | 4,000 | Q1 FY2026 call | — |
| Principality Stadium fan capacity | 74,000 | Q1 FY2026 call | — |
| RWJBarnabas Health beds | 5,700 | Q1 FY2026 call | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Specialty Business Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ARMK
this stock
Aramark
|
$15.22B | +54.1% | +6.4% | 43.2 | 3.9% |
|
CTAS
Cintas Corp
|
$71.09B | -3.7% | +6.4% | 37.6 | 3.0% |
|
RELX
Relx PLC
|
$56.10B | -20.7% | — | — | 0.2% |
|
TRI
Thomson Reuters Corp /Can/
|
$38.77B | -30.6% | — | — | 3.2% |
|
CPRT
Copart Inc
|
$25.64B | -27.6% | +24.7% | 17.3 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ARMK | -0.7% | +7.0% | +48.1% | -0.7% | +54.1% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -0.5% | +6.1% | +40.6% | -0.5% | +44.8% |
Capital returns
Latest dividend
$0.12
/ share · ex May 20, 2026
Paid (TTM)
$0.465
/ share · 4 payouts
Dividend yield (TTM, derived)
0.82%
Buyback program
· as of Nov 5, 2024
Authorized
$500.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1584509
CUSIP
03852U106
13F (30d)
38 filings
18 filers
Visit website
Investor relations